H. Pylori and Korea's Gastric Cancer Screening: The Evidence

South Korea's age-standardized gastric cancer incidence rate sits near 30 per 100,000 in recent GLOBOCAN estimates, several multiples above the global average and among the highest of any country tracked, trailing only Mongolia and Japan {Bray et al., 2024} {CA: A Cancer Journal for Clinicians}. Stomach cancer is not a rare disease anywhere in East Asia, but Korea's rate reflects a specific, well-characterized combination: a national Helicobacter pylori infection prevalence that has historically exceeded 50% of adults, layered on top of one of the highest average dietary sodium intakes in the developed world. Korea's policy response has been unusually direct — a national program of biennial upper endoscopy starting at age 40, run at a scale no other country has matched, plus a growing clinical and research push toward treating the underlying infection instead of only watching for the cancer it causes. The screening program has real, measured mortality benefit. The eradication strategy now has some of the strongest randomized evidence in all of cancer prevention behind it. The two approaches are not identical in their evidence quality, and conflating them obscures what is actually the more interesting finding: a bacterial infection, treated with a two-week course of antibiotics, measurably reduces the incidence of a solid tumor decades later.

• ENDOSCOPY, KOREAEver-screened adults show a 47% lower odds of gastric cancer death versus never-screened (OR 0.53)
• ERADICATION, POST-RESECTIONTreated patients had roughly half the rate of a second gastric cancer after endoscopic removal of a first (HR 0.50)
• ERADICATION, FAMILY HISTORYFirst-degree relatives who cleared infection had a 73% lower rate of new gastric cancer (HR 0.27)
• ERADICATION, 26.5-YEAR FOLLOW-UPChina's Fujian trial found a 43% overall risk reduction in a healthy population, sustained across a quarter-century
• ANTIBIOTIC RESISTANCEKorean clarithromycin resistance rose from roughly 7% (2009–2010) to 28.6% (2017–2019)

Korea's gastric cancer burden is a product of infection prevalence and diet, not genetics alone

The instinct to explain East Asia's gastric cancer rates as some fixed ethnic or genetic trait does not survive contact with the epidemiology. What distinguishes Korea, Japan, and parts of China is a shared exposure history: H. pylori colonization acquired in early childhood, at a time when crowded households and limited sanitation infrastructure made person-to-person and fecal-oral transmission routine, followed by decades of chronic gastritis that, in a meaningful minority of carriers, progresses through atrophic gastritis and intestinal metaplasia toward cancer. A Korean hospital-based case series found H. pylori seropositivity in 88% of early gastric cancer cases compared with 75% of matched controls, and the infection is estimated to raise gastric cancer risk by roughly fourfold on its own. Diet compounds this. A prospective cohort of more than 2.2 million Korean adults followed for six to seven years after baseline health examinations found a positive, dose-related association between self-reported salt preference and gastric cancer incidence, and the mechanistic literature points to high sodium intake damaging the gastric mucosa and promoting N-nitrosamine formation, both of which plausibly interact with H. pylori-driven inflammation rather than acting independently {Kim et al., 2010} {American Journal of Clinical Nutrition}. Korea's average daily salt intake has been estimated at more than double the World Health Organization's recommended ceiling, driven by a food culture built around jeotgal (salted seafood), heavily salted kimchi, and other fermented, high-sodium staples. Neither exposure alone explains Korea's rate; the combination of near-universal early-life infection and a diet that appears to accelerate the same carcinogenic pathway is what produces incidence figures this far above the global baseline.

Endoscopic screening shows a real, dose-dependent mortality benefit, but it is observational, not randomized

Korea's National Cancer Screening Program has offered gastric cancer screening to adults 40 and older since 1999, using either upper endoscopy or a barium-based upper gastrointestinal series, delivered on a two-year interval. No randomized controlled trial has tested whether inviting the general population to endoscopic screening reduces gastric cancer mortality — running that trial would require withholding a plausible cancer screening test from a randomized control arm at national scale, which is not something Korea, or any country with an established program, has been willing to do. The evidence instead comes from a large nested case-control study built on the national program's own registry data: more than 16.5 million Koreans aged 40 and older, with over 54,000 gastric cancer cases diagnosed between 2004 and 2009 and followed for vital status through 2012. Compared with never-screened individuals, those who had ever been screened by any modality showed a 21% lower odds of gastric cancer death (odds ratio 0.79). When the two screening modalities were separated, the entire effect concentrated in endoscopy: an odds ratio of 0.53 for upper endoscopy against essentially no benefit for the barium series (odds ratio 0.98) {Jun et al., 2017} {Gastroenterology}. The relationship also showed a clear dose-response pattern — one lifetime endoscopy carried an odds ratio of 0.60, two carried 0.32, and three or more carried 0.19 — which is the kind of gradient that strengthens a causal interpretation even in the absence of randomization. The honest caveat is that this remains a case-control design nested in observational data: people who present for endoscopy differ from people who do not in ways that are hard to fully adjust away, even in a system with high overall participation. The barium series comparison is useful here, since it shows the case-control method is capable of detecting no effect when a weaker test is used, which argues against the endoscopy finding being pure detection artifact or healthy-screener bias.

Randomized trials, not observational data, are what make the eradication case unusually strong

The H. pylori eradication literature is built on a genuinely different evidentiary foundation, and this is the part of the story that has shifted meaningfully in the last decade. The longest-running trial is the Fujian, China intervention, which randomized 1,630 asymptomatic, H. pylori-infected adults in a high-incidence region to eradication therapy or placebo starting in 1994 {Wong et al., 2004} {JAMA}. An updated analysis with 26.5 years of follow-up found a 43% reduction in gastric cancer incidence in the treatment group overall, rising to a 54% reduction among those in whom eradication was confirmed successful at the 7.5-year mark {Pan, Zhang et al., 2022} {Gastroenterology}. A separate, larger community trial in Linqu County, Shandong province, randomized more than 3,300 H. pylori-positive residents in a factorial design testing eradication against garlic and vitamin supplementation; after 14.7 years of follow-up, gastric cancer was diagnosed in 3.0% of the eradication group versus 4.6% of placebo (odds ratio 0.61), while garlic and vitamin supplementation showed no statistically significant effect on their own {Ma et al., 2012} {Journal of the National Cancer Institute}. Korea has since produced two of the more methodologically rigorous trials in this space, both published in the New England Journal of Medicine. The first randomized 396 patients who had already had one early gastric cancer removed endoscopically — a population known to be at elevated risk of a second, metachronous tumor — to eradication therapy or placebo; over a median 5.9 years, a new gastric cancer developed in 7.2% of the treatment group versus 13.4% of placebo, a hazard ratio of 0.50 {Choi et al., 2018} {New England Journal of Medicine}. The second, and arguably the more policy-relevant trial, enrolled 1,838 H. pylori-infected first-degree relatives of gastric cancer patients — a screened, high-risk but cancer-free general population, closer to what a national prevention program would actually target. Gastric cancer developed in 0.8% of those in whom infection was successfully eradicated versus 2.9% of those with persistent infection, a hazard ratio of 0.27 {Choi et al., 2020} {New England Journal of Medicine}. Across four independent trial populations, spanning three countries and three different risk strata, the point estimates cluster in a fairly narrow band — roughly a 40 to 70% relative reduction in gastric cancer risk from eradicating an infection most people acquired in early childhood and would otherwise have carried for life.

Timing of eradication and the point of no return in gastric premalignancy

The consistency across trials should not be read as evidence that eradication timing does not matter, because the mechanistic and histologic data argue the opposite. H. pylori-driven carcinogenesis is understood to proceed through a sequence — chronic gastritis, atrophic gastritis, intestinal metaplasia, dysplasia, carcinoma — and eradication interrupts the pathway most effectively before intestinal metaplasia has become established, after which the mucosal changes appear to be substantially less reversible. In the Korean post-resection trial, histologic improvement in atrophic gastritis at the gastric corpus was observed in 48.4% of the treatment group versus 15.0% of placebo, showing that eradication produces measurable tissue-level reversal even in a population that had already developed one cancer — but the trial's cancer-reduction effect, a hazard ratio of 0.50, is smaller than the 0.27 seen in the first-degree relatives trial, where participants were cancer-free at enrollment and presumably earlier in the premalignant sequence on average. This pattern — larger relative risk reduction in less-advanced populations — is consistent with, though not proof of, a "point of no return" model in which eradication delivered before intestinal metaplasia sets in prevents more cancers than eradication delivered after. It is also the central open question for any population-wide screen-and-treat policy: eradicating infection in 40-year-olds who have carried H. pylori since childhood may capture meaningfully less benefit than eradicating it in adolescents or young adults, but no trial has directly randomized eradication timing by age band with cancer incidence as the endpoint, largely because such a trial would require decades of follow-up before yielding a readable result.

Rising antibiotic resistance is already eroding real-world eradication rates in Korea

The trial data describe what happens when eradication succeeds; a separate and growing body of Korean surveillance data shows that eradication is succeeding less often than it used to. Standard triple therapy — a proton pump inhibitor with amoxicillin and clarithromycin — was the default first-line regimen throughout the period the major trials were conducted, but Korean resistance surveillance has tracked clarithromycin resistance rising from roughly 7% in 2009–2010 to about 16% in 2011–2012, and reaching 28.6% in single-center data from 2017–2019 {Lee et al., 2019} {Helicobacter / Korean antimicrobial resistance surveillance}. Dual resistance to clarithromycin and metronidazole has also become more common over the same period. Because triple therapy's efficacy depends heavily on clarithromycin susceptibility, rising resistance translates directly into falling real-world eradication rates, which is why Korean gastroenterology practice has shifted toward susceptibility-guided regimen selection and toward bismuth-based quadruple therapy as an empiric first-line option in areas of high resistance. This matters for population-level prevention math in a very concrete way: a screen-and-treat program's expected reduction in cancer incidence is a function of both the trial-derived relative risk reduction and the actual eradication success rate achieved in practice, and the second number is moving in the wrong direction. None of the major RCTs cited above were conducted in a high clarithromycin-resistance environment, so their effect sizes should be read as a ceiling that real-world Korean eradication programs, run with 2020s-era antibiotic susceptibility, may not fully reach without resistance-adapted protocols.

Screen-and-treat is gaining international backing, but cost-effectiveness and implementation questions remain open

The strength of the trial evidence has moved this from a research question to an active policy one. An International Agency for Research on Cancer working group, convening interdisciplinary experts from 21 countries, published formal guidance in early 2026 concluding that population-based H. pylori screen-and-treat programs represent a viable, evidence-supported strategy for gastric cancer prevention and should be considered by national health authorities, particularly in high-incidence settings {IARC Working Group, 2026} {New England Journal of Medicine}. Only a small number of population-scale programs have actually been implemented anywhere in the world to date — the Matsu Islands off Taiwan built one of the earliest, and Japan has moved toward broad H. pylori treatment coverage through its national insurance system — which means most of what is known about program-level (as opposed to trial-level) effectiveness still comes from a handful of natural experiments rather than a mature evidence base. Korean researchers are now running formal cost-effectiveness modeling comparing the current endoscopy-only strategy against a hybrid approach — H. pylori testing and eradication added at age 40, with endoscopic surveillance continuing afterward — specifically because the answer is not obvious from the trial data alone. Eradication is a one-time, relatively low-cost intervention with a multi-decade payoff horizon, while endoscopy is a recurring cost that also catches cancers unrelated to H. pylori and detects early lesions in people already along the premalignant pathway; a program that dropped endoscopic screening in favor of eradication alone would likely miss both cancers in already-infected older adults with existing mucosal damage and the minority of gastric cancers not attributable to H. pylori at all. The more probable direction for Korean policy, on the evidence currently available, is not replacement but layering — eradication as an added, earlier intervention, endoscopy retained as the backstop for the population and disease subset it already screens effectively.

Synthesis: two prevention strategies with different evidentiary maturity, both credible on their own terms

Korea's gastric cancer burden and its policy response form one of the cleaner cause-and-effect stories in modern preventive medicine, but it is a story with two distinct evidentiary strands that deserve separate scrutiny. Endoscopic screening's mortality benefit rests on large, well-constructed observational data with a convincing dose-response gradient, which is strong evidence by observational standards but not the same as a randomized trial — and likely never will be, since randomizing a national population away from an already-established screening test is not ethically or politically viable at this point. H. pylori eradication's cancer-prevention effect, by contrast, now rests on multiple independent randomized controlled trials, run in different countries and different risk populations, with concordant point estimates and one dataset extending past a quarter-century of follow-up — a level of causal evidence that few cancer prevention strategies of any kind can claim. What remains genuinely unresolved is not whether eradication works, but how to deploy it well: at what age it captures the most benefit before premalignant changes become fixed, how to sustain eradication success as antibiotic resistance climbs, and whether the incremental cost of screen-and-treat, layered on top of an already-effective endoscopy program, is worth the price relative to other uses of the same health budget. Korea sits in an unusual position to answer these questions before most other high-incidence countries do, given that it already has the screening infrastructure, the disease burden, and now the trial evidence in hand.

James Whitfield is the Preventive Care Editor at HealthKoLab. He holds a Master of Public Health from Johns Hopkins Bloomberg School and is a former epidemiological researcher focused on cardiovascular risk assessment and population health strategies.